EMEA approves abiraterone acetate for treatment of mCRPC

Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.

Abiraterone acetate will still need approval from the European Commission before it can actually be prescribed in the EU nations, but such approval usually occurs within a few months of a decision by EMEA. And of course an approval will still be followed by country-specific negotiations about the cost of abiraterone acetate before it can actually be covered under the national health systems of nations like the UK and Germany.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: